Literature DB >> 22142023

Interleukin-4 -590T/C polymorphism influences the susceptibility to nonsmall cell lung cancer.

Xiaoyan Li1, Weiwei Shi, Guanzhen Yu, Li Lin, Bo Yang, Jianxiong Li, Wanfeng Guo, Chuanhao Tang, Hong Wang, Hongjun Gao, Haifeng Qin, Yi Liu, Xiaoqing Liu.   

Abstract

Lung cancer is the leading cause of cancer mortality worldwide. Nonsmall cell lung cancer (NSCLC) accounts for most of these cases. Interleukin 4 (IL-4) is a typical pleiotropic T helper 2 cytokine and plays crucial roles in tumor immunology. IL-4 gene -590T/C polymorphism has been shown to be associated with different autoimmune diseases and cancers. The present study evaluated the correlation between this polymorphism and the susceptibility to NSCLC in the Chinese population. The IL-4 variant -590T/C was detected by polymerase chain reaction-restriction fragment length polymorphism in 1072 NSCLC cases and 1126 age-matched healthy controls. Data were analyzed using the Chi-square test. Results showed that frequencies of IL-4 -590 TC, CC genotype, and -590 C allele were significantly lower in patients with NSCLC than in healthy controls (odds ratio [OR]=0.77, 95% confidence interval [CI] 0.64-0.93, p=0.006; OR=0.54, 95% CI 0.38-0.76, p=0.0004; and OR=0.72, 95% CI 0.62-0.83, p=1.1 × 10(-5), respectively). Our data suggest that the -590T/C polymorphism of the IL-4 gene is associated with a decreased susceptibility to NSCLC.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22142023     DOI: 10.1089/dna.2011.1425

Source DB:  PubMed          Journal:  DNA Cell Biol        ISSN: 1044-5498            Impact factor:   3.311


  11 in total

1.  Circulating follicular helper T cells in Crohn's disease (CD) and CD-associated colorectal cancer.

Authors:  Zhenlong Wang; Zhiming Wang; Yanqing Diao; Xiaoli Qian; Nan Zhu; Wen Dong
Journal:  Tumour Biol       Date:  2014-06-19

2.  Genetic polymorphisms of IL-6 and IL-10 genes correlate with lung cancer in never-smoking Han population in China.

Authors:  Ying-Min Zhang; Yi-Min Mao; Yu-Xia Sun
Journal:  Int J Clin Exp Med       Date:  2015-01-15

3.  Effects of lysyl oxidase genetic variants on the susceptibility to rhegmatogenous retinal detachment and proliferative vitreoretinopathy.

Authors:  Honghua Yu; Tao Li; Xiulan Zou; Ling Yuan; Jie Hu; Zhe Xu; Lianghong Peng; Chu Zhang; Yuping Zou
Journal:  Inflammation       Date:  2013-08       Impact factor: 4.092

Review 4.  Cellular and molecular immunology of lung cancer: therapeutic implications.

Authors:  Austin Huy Nguyen; Ilya G Berim; Devendra K Agrawal
Journal:  Expert Rev Clin Immunol       Date:  2014-10-28       Impact factor: 4.473

5.  The effect of lysyl oxidase polymorphism on susceptibility and prognosis of nonsmall cell lung cancer.

Authors:  Weiwei Shi; Bo Yang; Xiaoyan Li; Shengjie Sun; Lijie Wang; Shunchang Jiao
Journal:  Tumour Biol       Date:  2012-09-05

6.  Level of plasmacytoid dendritic cells is increased in non-small cell lung carcinoma.

Authors:  Weiwei Shi; Xiaoyan Li; Jerry L Porter; David H Ostrodi; Bo Yang; Juan Li; Yishang Wang; Juan Zhang; Li Bai; Shunchang Jiao
Journal:  Tumour Biol       Date:  2013-10-18

7.  Associations of common IL-4 gene polymorphisms with cancer risk: A meta-analysis.

Authors:  Yingxian Jia; Xiaochuan Xie; Xiaohan Shi; Shangwei Li
Journal:  Mol Med Rep       Date:  2017-06-20       Impact factor: 2.952

8.  Association between IL-4 tagging single nucleotide polymorphisms and the risk of lung cancer in China.

Authors:  Nan Tan; Jiangjiang Song; Mengdan Yan; Jiamin Wu; Yao Sun; Zichao Xiong; Yipeng Ding
Journal:  Mol Genet Genomic Med       Date:  2019-02-06       Impact factor: 2.183

9.  Three common polymorphisms in the IL-4 gene and cancer risk: a meta-analysis involving 5,392 cases and 6,930 controls.

Authors:  Li Zhenzhen; Liu Xianghua; Wang Qingwei; Guo Zhan; Sun Ning
Journal:  Tumour Biol       Date:  2013-04-10

Review 10.  The Treg/Th17 paradigm in lung cancer.

Authors:  Min-Chao Duan; Xiao-Ning Zhong; Guang-Nan Liu; Jin-Ru Wei
Journal:  J Immunol Res       Date:  2014-04-29       Impact factor: 4.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.